Literature DB >> 19358223

The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis.

Huei-Ting Tsai1, Kari E North, Suzanne L West, Charles Poole.   

Abstract

To elucidate a widely suspected but inconclusive association between rs6280 in the dopamine receptor 3 gene (DRD3) and prevalence of tardive dyskinesia (TD), we conducted a meta-analysis of studies obtained in a systematic search of several bibliographic systems. We conducted several analyses of funnel plot asymmetry, overall heterogeneity, and study characteristics in analyses analogous to general, dominant and recessive inheritance models with the prevalence odds ratio (POR) as the measure of association. Thirteen eligible studies were identified with publication dates between 1997 and 2008. Evidence of funnel plot asymmetry was discerned in the dominant and general model analyses, but not in the recessive model analysis. Stratified analyses indicated that publication year, TD assessment method (Schooler-Kane criteria or other) and TD assessment frequency (single or repeated) were important study characteristics associated with heterogeneous PORs across studies. Studies conducted among patients with older age, fewer women or European (compared with Asian) ancestry reported stronger average PORs. Summary POR estimates under the dominant and general inheritance models were not warranted due to funnel plot asymmetry and heterogeneity. Under the recessive model, the summary estimate was POR = 0.93 (95% confidence interval: 0.70-1.23). We conclude that there is no or little association between DRD3 rs6280 polymorphisms and prevalence of TD. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19358223     DOI: 10.1002/ajmg.b.30946

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  19 in total

1.  Erratum to: Letter to the Editor: The ongoing tyranny of statistical significance testing in biomedical research.

Authors:  Tyler J VanderWeele
Journal:  Eur J Epidemiol       Date:  2010-12       Impact factor: 8.082

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

3.  Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Authors:  Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-06-01

Review 4.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

5.  BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.

Authors:  Itaru Miura; Jian-Ping Zhang; Masahiro Nitta; Todd Lencz; John M Kane; Anil K Malhotra; Hirooki Yabe; Christoph U Correll
Journal:  Schizophr Res       Date:  2014-01-07       Impact factor: 4.939

Review 6.  Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Authors:  Gavin P Reynolds; Olga O McGowan; Caroline F Dalton
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 7.  Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.

Authors:  Kazunari Yoshida; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2018-09-26

Review 8.  Genetics of antipsychotic-induced side effects and agranulocytosis.

Authors:  Nabilah I Chowdhury; Gary Remington; James L Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-04       Impact factor: 5.285

Review 9.  The genetics of drug-related movement disorders, an umbrella review of meta-analyses.

Authors:  Nadine C van der Burg; Asmar F Y Al Hadithy; Peter N van Harten; Jim van Os; P Roberto Bakker
Journal:  Mol Psychiatry       Date:  2020-02-04       Impact factor: 15.992

10.  No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients.

Authors:  Il-Soo Kim; Ho-Kyoung Yoon; Seung-Gul Kang; Young-Min Park; Yong-Ku Kim; Seung-Hyun Kim; Jung-Eun Choi; Leen Kim; Heon-Jeong Lee
Journal:  Psychiatry Investig       Date:  2012-05-22       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.